He Q, Li JK, Li F, Li RG, Zhan GQ, Li G, Du WX, Tan HB. Mechanism of action of gypenosides on type 2 diabetes and non-alcoholic fatty liver disease in rats. World J Gastroenterol 2015; 21(7): 2058-2066 [PMID: 25717238 DOI: 10.3748/wjg.v21.i7.2058]
Corresponding Author of This Article
Hua-Bing Tan, Professor, Department of Infectious Diseases and Lab of Liver Disease, Renmin Hospital, Hubei University of Medicine, 39 Chaoyangzhong Road, Shiyan 442000, Hubei Province, China. tanhb_2013@163.com
Research Domain of This Article
Biochemistry & Molecular Biology
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Feb 21, 2015; 21(7): 2058-2066 Published online Feb 21, 2015. doi: 10.3748/wjg.v21.i7.2058
Mechanism of action of gypenosides on type 2 diabetes and non-alcoholic fatty liver disease in rats
Qin He, Jin-Ke Li, Fang Li, Ru-Gui Li, Guo-Qing Zhan, Gang Li, Wei-Xing Du, Hua-Bing Tan
Qin He, Jin-Ke Li, Fang Li, Ru-Gui Li, Guo-Qing Zhan, Gang Li, Wei-Xing Du, Hua-Bing Tan, Department of Infectious Diseases and Lab of Liver Disease, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, Hubei Province, China
Author contributions: He Q and Li G performed the majority of experiments; Li F performed the literature research; Zhan GQ and Li G performed the data acquisition and data analysis; Li G drafted the manuscript; Tan HB designed the whole study and reviewed the manuscript; all authors read and approved the final manuscript.
Supported by Bureau of Public Health of Hubei Province.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Hua-Bing Tan, Professor, Department of Infectious Diseases and Lab of Liver Disease, Renmin Hospital, Hubei University of Medicine, 39 Chaoyangzhong Road, Shiyan 442000, Hubei Province, China. tanhb_2013@163.com
Telephone: +86-719-8637659 Fax: +86-719-8637659
Received: June 18, 2014 Peer-review started: June 19, 2014 First decision: July 21, 2014 Revised: September 3, 2014 Accepted: November 18, 2014 Article in press: November 19, 2014 Published online: February 21, 2015 Processing time: 238 Days and 0.8 Hours
Core Tip
Core tip: Gypenosides (GPs) are one of the most pharmacologically active components in G. pentaphyllum. Intervention with GPs significantly decreased the levels of aspartate aminotransferase, alanine aminotransferase, blood glucose, insulin, triglycerides and total cholesterol in type 2 diabetes mellitus and non-alcoholic fatty liver disease (T2DM-NAFLD) model rats, down-regulated the expression of TNF-α, NF-κB, rabbit anti-proliferator activated receptory (PPARγ) and rabbit anti-cytochrome P4501A1 (CYP1A1) mRNA, decreased the infiltration of liver fats and reversed the histopathological changes in a dose-dependent manner. These findings suggest that GPs have a protective effect against T2DM-NAFLD by down-regulating the expression of TNF-α and NF-κB proteins, and PPARγ and CYP4501A1 mRNAs.
